213x Filetype XLSX File size 0.10 MB Source: effectivehealthcare.ahrq.gov
Table F-1. Cannabis RCTs study characteristics Crossover PMID Author, Year Study Design Design Setting 16282192 Blake, 2006 RCT No Europe 33118602 Chaves, 2020 RCT No Brazil 27720917 de Vries, 2017 RCT No Europe 32770831 Eibach, 2020 RCT Yes Europe 18182416 Frank, 2008 RCT Yes Europe 23180178 Langford, 2013 RCT No Europe 23742737 Lynch, 2014 RCT Yes Canada 17997224 Nurmikko, 2007 RCT No Europe 23070400 Pini, 2012 RCT Yes Europe 20855984 Rintala, 2010 RCT Yes U.S. 16186518 Rog, 2005 RCT No Europe 29073592 Schimrigk, 2017 RCT No Europe 19808912 Selvarajah, 2010 RCT No Europe 24420962 Serpell, 2014 RCT No Europe 17974490 Skrabek, 2008 RCT No Canada 22921260 Toth, 2012 RCT No Canada 25288189 Turcotte, 2015 RCT No Canada 16988792 Wissel, 2006 RCT Yes Germany 31793418 Xu, 2020 RCT No U.S. 22791906 Zajicek, 2012 RCT No Europe Abbreviations: CBD = cannabidiol; HIV = human immunodeficiency virus; NA = not applicable; NPP = neuropathic pain; NR = not reported; RCT = randomized controlled trial; THC = tetrahydrocannabinol; U.S. = United States Age Measure Pain Population Pain Condition (Mean, Median) Age, Years Female % Race, White % Inflammatory arthritis Rheumatoid arthritis Mean 63 79 NR Fibromyalgia Fibromyalgia Mean 52 100 NR Chronic pancreatitis and postsurgical abdominal Visceral pain pain Mean 53 50 96 NPP HIV-associated Mean 50 3 NR NPP NR Mean 50 23 NR NPP Multiple sclerosis Mean 49 68 98 Chemotherapy-induced NPP neuropathic pain Mean 56 83 NR NPP Mixed Mean 53 59 NR Medication overuse Headache headache Mean 53 67 NR
no reviews yet
Please Login to review.